Cullinan Oncology is a biopharmaceutical company strategically built to develop a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The company focuses on identifying and developing promising therapeutic candidates, leveraging a hub-and-spoke model to advance multiple programs efficiently. Their mission is to create new standards of care for patients with cancer by bringing innovative treatments from discovery through clinical development and commercialization.
Serves as the central hub for strategic leadership, research and development oversight, clinical operations management, corporate development, finance, and administrative functions.
State-of-the-art office facilities within a prominent commercial building in Kendall Square, offering proximity to leading academic institutions, research centers, and biotech peers. The location provides access to a rich innovation ecosystem and talent pool.
Fosters a dynamic, innovative, and collaborative environment, characteristic of leading biotech companies. The culture emphasizes scientific excellence, urgency in addressing patient needs, and teamwork.
Its Cambridge location in Kendall Square places Cullinan Oncology at the epicenter of biopharmaceutical innovation, facilitating collaborations, partnerships, and access to cutting-edge research and talent.
While headquartered in the United States (Cambridge, MA), Cullinan Oncology has a global outlook for its drug development programs. The company conducts clinical trials in multiple countries and collaborates with international research institutions, investigators, and contract research organizations (CROs) to advance its pipeline. This global approach supports the development and potential future commercialization of its oncology therapies for patients worldwide, though it does not operate a widespread network of international physical offices.
One Main Street, Suite 1350
Cambridge
MA
USA
Address: Cullinan Oncology centralizes its core operations at its Cambridge, MA headquarters.
Global reach is achieved through strategic partnerships and clinical trial sites rather than multiple physical offices.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cullinan Therapeutics' leadership includes:
Cullinan Therapeutics has been backed by several prominent investors over the years, including:
Over the last 12 months, Cullinan Oncology notably expanded its leadership by appointing a new Chief Operating Officer to support its growing pipeline and operational scale. No major executive departures were publicly announced during this period, indicating stability in the senior leadership team.
Discover the tools Cullinan Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cullinan Oncology likely utilizes standard corporate email formats for its employees, typically combining parts of an employee's name with the company domain '@cullinanoncology.com'. Common conventions include first initial followed by last name, or first name separated from the last name by a dot.
[first_initial][last]@cullinanoncology.com (e.g., jdoe@cullinanoncology.com) is a common pattern. Another possibility is [first].[last]@cullinanoncology.com.
Format
nahmed@cullinanoncology.com
Example
80%
Success rate
Business Wire • May 9, 2024
Cullinan Oncology announced its Q1 2024 financial results, highlighting progress in its clinical programs, including CLN-049 in AML and CLN-619 in solid tumors, and detailed upcoming milestones. The company affirmed a strong cash position to fund operations into 2026....more
Business Wire • February 28, 2024
Cullinan Oncology reported its financial results for Q4 and full-year 2023, along with a corporate update on its pipeline advancements, including progress with CLN-049, CLN-619, and other key programs....more
Business Wire • December 7, 2023
Cullinan Oncology presented updated positive clinical data for its CD123xCD3 T cell engager, CLN-049, at the American Society of Hematology (ASH) 2023 Annual Meeting, demonstrating anti-leukemic activity and a manageable safety profile in patients with r/r AML and MDS....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cullinan Therapeutics, are just a search away.